Ronit Yerushalmi

3.0k total citations
105 papers, 1.9k citations indexed

About

Ronit Yerushalmi is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Ronit Yerushalmi has authored 105 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Hematology, 41 papers in Oncology and 24 papers in Genetics. Recurrent topics in Ronit Yerushalmi's work include Hematopoietic Stem Cell Transplantation (54 papers), Acute Myeloid Leukemia Research (40 papers) and Acute Lymphoblastic Leukemia research (20 papers). Ronit Yerushalmi is often cited by papers focused on Hematopoietic Stem Cell Transplantation (54 papers), Acute Myeloid Leukemia Research (40 papers) and Acute Lymphoblastic Leukemia research (20 papers). Ronit Yerushalmi collaborates with scholars based in Israel, United States and France. Ronit Yerushalmi's co-authors include Avichai Shimoni, Arnon Nagler, Noga Shem‐Tov, Abraham Avigdor, Izhar Hardan, Ivetta Danylesko, I Ben-Bassat, Moshe Yeshurun, Roni Shouval and Eyal Sheiner and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Ronit Yerushalmi

98 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ronit Yerushalmi Israel 24 1.0k 772 435 407 273 105 1.9k
Noga Shem‐Tov Israel 23 1.0k 1.0× 584 0.8× 409 0.9× 291 0.7× 205 0.8× 85 1.7k
Barbara Degar United States 20 1.1k 1.1× 514 0.7× 352 0.8× 696 1.7× 236 0.9× 48 2.5k
Richard Champlin United States 19 1.1k 1.0× 638 0.8× 428 1.0× 251 0.6× 191 0.7× 52 1.7k
Nina Worel Austria 28 1.5k 1.4× 627 0.8× 216 0.5× 534 1.3× 344 1.3× 122 2.3k
Aleksandr Lazaryan United States 21 678 0.7× 797 1.0× 200 0.5× 443 1.1× 142 0.5× 103 1.7k
Jean‐Pierre Jouet France 17 1.5k 1.5× 443 0.6× 379 0.9× 372 0.9× 340 1.2× 39 1.9k
Diane Coso France 25 929 0.9× 582 0.8× 278 0.6× 309 0.8× 318 1.2× 78 1.7k
Melhem Solh United States 26 1.1k 1.0× 1.2k 1.5× 268 0.6× 586 1.4× 308 1.1× 136 2.1k
Eefke Petersen Netherlands 21 924 0.9× 446 0.6× 223 0.5× 450 1.1× 251 0.9× 69 1.7k
Christoph Faul Germany 22 1.1k 1.1× 1.3k 1.7× 902 2.1× 608 1.5× 272 1.0× 82 2.5k

Countries citing papers authored by Ronit Yerushalmi

Since Specialization
Citations

This map shows the geographic impact of Ronit Yerushalmi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ronit Yerushalmi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ronit Yerushalmi more than expected).

Fields of papers citing papers by Ronit Yerushalmi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ronit Yerushalmi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ronit Yerushalmi. The network helps show where Ronit Yerushalmi may publish in the future.

Co-authorship network of co-authors of Ronit Yerushalmi

This figure shows the co-authorship network connecting the top 25 collaborators of Ronit Yerushalmi. A scholar is included among the top collaborators of Ronit Yerushalmi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ronit Yerushalmi. Ronit Yerushalmi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shouval, Roni, Shalev Fried, Ivetta Danylesko, et al.. (2025). Pretreatment pulmonary function testing has limited utility in B-cell lymphoma treated with CD19 CAR T cells. Blood Advances. 9(7). 1720–1725. 1 indexed citations
2.
Danylesko, Ivetta, Noga Shem‐Tov, Ronit Yerushalmi, et al.. (2024). Point of care CD19 chimeric antigen receptor (CAR) T-cells for relapsed/refractory acute myeloid leukemia (AML) with aberrant CD19 antigen expression. Current Research in Translational Medicine. 72(4). 103471–103471. 5 indexed citations
3.
Youngster, Ilan, Ivetta Danylesko, Israel Henig, et al.. (2024). Fecal microbiota transplantation in capsules for the treatment of steroid refractory and steroid dependent acute graft vs. host disease: a pilot study. Bone Marrow Transplantation. 59(3). 409–416. 7 indexed citations
4.
Magen, Hila, Shalev Fried, Orit Itzhaki, et al.. (2023). POINT‐OF‐CARE ANTI‐BCMA CAR T‐CELL THERAPY INDUCES ENCOURAGING RESPONSE RATES IN HIGH‐RISK RELAPSED/REFRACTORY MULTIPLE MYELOMA. Hematological Oncology. 41(S2). 82–83. 1 indexed citations
5.
Fried, Shalev, Ivetta Danylesko, Orit Itzhaki, et al.. (2023). High Response Rates Following Point-of-Care Anti-CD19 CAR T-Cell Therapy in Adults with Relapsed/Refractory Acute B Lymphoblastic Leukemia. Blood. 142(Supplement 1). 6875–6875.
6.
Fried, Shalev, Orit Itzhaki, Ronit Yerushalmi, et al.. (2023). Point-of-care anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory follicular lymphoma. Leukemia & lymphoma. 64(12). 1956–1963. 3 indexed citations
7.
Danylesko, Ivetta, Noga Shem‐Tov, Ronit Yerushalmi, et al.. (2023). P520: POINT OF CARE CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH ABERRANT CD19 ANTIGEN EXPRESSION. HemaSphere. 7(S3). e4369964–e4369964. 1 indexed citations
8.
Fried, Shalev, Roni Shouval, Nira Varda‐Bloom, et al.. (2022). Point-of-care CAR T-cell therapy as salvage strategy for out-of-specification tisagenlecleucel. Leukemia & lymphoma. 63(14). 3385–3393. 5 indexed citations
9.
Kedmi, Meirav, Roni Shouval, Shalev Fried, et al.. (2022). Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B-cell lymphoma. Transplantation and Cellular Therapy. 28(5). 251–257. 24 indexed citations
10.
Pasvolsky, Oren, Shai Shimony, Ron Ram, et al.. (2021). Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study. Annals of Hematology. 101(2). 379–387. 23 indexed citations
11.
Ganzel, Chezi, Ron Ram, Alexander Gural, et al.. (2020). Venetoclax is safe and efficacious in relapsed/refractory AML. Leukemia & lymphoma. 61(9). 2221–2225. 30 indexed citations
12.
Danylesko, Ivetta, Roni Shouval, Noga Shem‐Tov, et al.. (2020). Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma. Bone Marrow Transplantation. 56(5). 1134–1143. 23 indexed citations
13.
Shouval, Roni, Joshua Fein, Ivetta Danylesko, et al.. (2020). LDH and renal function are prognostic factors for long-term outcomes of multiple myeloma patients undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation. 55(9). 1736–1743. 12 indexed citations
14.
Fein, Joshua, Avichai Shimoni, Myriam Labopin, et al.. (2018). The impact of individual comorbidities on non-relapse mortality following allogeneic hematopoietic stem cell transplantation. Leukemia. 32(8). 1787–1794. 31 indexed citations
15.
Shouval, Roni, Joshua Fein, Ivetta Danylesko, et al.. (2017). Determinants for Oral Mucositis in Allogeneic Hematopoietic Stem Cell Transplantation: Prospective Evaluation and Risk Analysis. Blood. 130. 3239–3239. 1 indexed citations
16.
Danylesko, Ivetta, Nira Varda‐Bloom, Ronit Yerushalmi, et al.. (2015). Plerixafor (Mozobil): A Stem Cell-Mobilizing Agent for Transplantation in Lymphoma Patients Predicted to Be Poor Mobilizers - A Pilot Study. Acta Haematologica. 135(1). 29–36. 8 indexed citations
17.
Yerushalmi, Ronit, Noga Shem‐Tov, Ivetta Danylesko, et al.. (2015). Fludarabine and treosulfan compared with other reduced-intensity conditioning regimens for allogeneic stem cell transplantation in patients with lymphoid malignancies. Bone Marrow Transplantation. 50(12). 1526–1535. 15 indexed citations
18.
Besser, Michal J., Ronnie Shapira‐Frommer, Orit Itzhaki, et al.. (2013). Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies. Clinical Cancer Research. 19(17). 4792–4800. 294 indexed citations
19.
Shimoni, Avichai, Izhar Hardan, Francis Ayuk, et al.. (2010). Allogenic hematopoietic stem‐cell transplantation with reduced‐intensity conditioning in patients with refractory and recurrent multiple myeloma. Cancer. 116(15). 3621–3630. 32 indexed citations
20.
Shimoni, Avichai, S. Tzila Zwas, Izhar Hardan, et al.. (2007). Yttrium-90–ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma. Experimental Hematology. 35(4). 534–540. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Noga Shem‐Tov Breakdown of academic impact, for papers by Barbara Degar Breakdown of academic impact, for papers by Richard Champlin Breakdown of academic impact, for papers by Nina Worel Breakdown of academic impact, for papers by Aleksandr Lazaryan Breakdown of academic impact, for papers by Jean‐Pierre Jouet Breakdown of academic impact, for papers by Diane Coso Breakdown of academic impact, for papers by Melhem Solh Breakdown of academic impact, for papers by Eefke Petersen Breakdown of academic impact, for papers by Christoph Faul
Rankless by CCL
2026